 "coronavirus vaccine")
MOSCOW (Reuters) - Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.
Click here to connect with us on WhatsApp
Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.
(Reporting by Polina Nikolskaya, writing by Maria Kiselyova; editing by Alexander Marrow)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
